JP6858185B2 - 増殖性および炎症性疾患の処置における抗ＴｆＲ抗体およびその使用 - Google Patents

増殖性および炎症性疾患の処置における抗ＴｆＲ抗体およびその使用 Download PDF

Info

Publication number
JP6858185B2
JP6858185B2 JP2018522867A JP2018522867A JP6858185B2 JP 6858185 B2 JP6858185 B2 JP 6858185B2 JP 2018522867 A JP2018522867 A JP 2018522867A JP 2018522867 A JP2018522867 A JP 2018522867A JP 6858185 B2 JP6858185 B2 JP 6858185B2
Authority
JP
Japan
Prior art keywords
antibody
seq
tfr
protein
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018522867A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018521691A (ja
JP2018521691A5 (OSRAM
Inventor
ローネー，ピエール
ベランガー，コラリー
スーシェ，エルヴェ
Original Assignee
イナサリス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イナサリス filed Critical イナサリス
Publication of JP2018521691A publication Critical patent/JP2018521691A/ja
Publication of JP2018521691A5 publication Critical patent/JP2018521691A5/ja
Application granted granted Critical
Publication of JP6858185B2 publication Critical patent/JP6858185B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2018522867A 2015-07-22 2016-07-21 増殖性および炎症性疾患の処置における抗ＴｆＲ抗体およびその使用 Active JP6858185B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306192.4 2015-07-22
EP15306192 2015-07-22
PCT/EP2016/067465 WO2017013230A1 (en) 2015-07-22 2016-07-21 ANTI-TfR ANTIBODIES AND THEIR USE IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS

Publications (3)

Publication Number Publication Date
JP2018521691A JP2018521691A (ja) 2018-08-09
JP2018521691A5 JP2018521691A5 (OSRAM) 2019-08-29
JP6858185B2 true JP6858185B2 (ja) 2021-04-14

Family

ID=53776520

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018522867A Active JP6858185B2 (ja) 2015-07-22 2016-07-21 増殖性および炎症性疾患の処置における抗ＴｆＲ抗体およびその使用

Country Status (22)

Country Link
US (2) US11230605B2 (OSRAM)
EP (1) EP3325509B1 (OSRAM)
JP (1) JP6858185B2 (OSRAM)
KR (1) KR102690998B1 (OSRAM)
CN (1) CN107849136B (OSRAM)
AU (1) AU2016296321B2 (OSRAM)
CA (1) CA2992509C (OSRAM)
CY (1) CY1123941T1 (OSRAM)
DK (1) DK3325509T3 (OSRAM)
ES (1) ES2860988T3 (OSRAM)
HR (1) HRP20210393T1 (OSRAM)
HU (1) HUE053296T2 (OSRAM)
IL (1) IL257065B (OSRAM)
LT (1) LT3325509T (OSRAM)
MX (1) MX2018000569A (OSRAM)
PL (1) PL3325509T3 (OSRAM)
PT (1) PT3325509T (OSRAM)
RS (1) RS61586B1 (OSRAM)
RU (1) RU2737637C2 (OSRAM)
SI (1) SI3325509T1 (OSRAM)
SM (1) SMT202100134T1 (OSRAM)
WO (1) WO2017013230A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI787796B (zh) 2015-05-04 2022-12-21 美商Ｃｙｔｏｍｘ生物製藥公司 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法
FR3062213B1 (fr) 2017-01-20 2021-02-26 Endodiag Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose
EP3552631A1 (en) * 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
JP2021533200A (ja) 2018-08-02 2021-12-02 ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. 顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US20210308273A1 (en) 2018-08-02 2021-10-07 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP4069745A4 (en) * 2019-11-06 2024-05-29 The Regents Of The University Of California COMPOSITIONS AND METHODS FOR TRANSFERRIN RECEPTOR 1 TARGETING
MX2022009418A (es) * 2020-01-31 2022-08-25 Dyne Therapeutics Inc Anticuerpo del receptor anti-transferrina (tfr) y usos del mismo.
US11638761B2 (en) * 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11648318B2 (en) 2021-07-09 2023-05-16 Dyne Therapeutics, Inc. Anti-transferrin receptor (TFR) antibody and uses thereof
EP4366784A1 (en) 2021-07-09 2024-05-15 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) * 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11827702B2 (en) 2021-09-01 2023-11-28 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
TW202330601A (zh) * 2021-09-13 2023-08-01 德州大學系統董事會 ＴｆＲ抗原結合蛋白及其用途
KR20250004770A (ko) * 2022-04-15 2025-01-08 다인 세라퓨틱스, 인크. 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제
CN120282983A (zh) * 2022-12-02 2025-07-08 百奥赛图(北京)医药科技股份有限公司 抗tfr1抗体及其应用
CN120958020A (zh) 2023-03-24 2025-11-14 戴纳立制药公司 Aβ靶向蛋白和使用方法
EP4477236A1 (en) 2023-06-14 2024-12-18 Inatherys Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics
TW202517685A (zh) * 2023-10-26 2025-05-01 美商百健Ｍａ公司 抗運鐵蛋白受體抗體及其用途
WO2025140522A1 (en) * 2023-12-29 2025-07-03 Nona Biosciences (Suzhou) Co., Ltd. Anti-tfr1 antibodies, preparation methods and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434156A (en) 1981-10-26 1984-02-28 The Salk Institute For Biological Studies Monoclonal antibodies specific for the human transferrin receptor glycoprotein
BR0008758A (pt) * 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
CA2802205C (en) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2005011082A2 (en) 2003-07-23 2005-02-03 Univeral Infusion Technology Drive motor transmission system
EP1740616B1 (en) * 2004-04-30 2011-12-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-tfr antibody.
US7572895B2 (en) * 2004-06-07 2009-08-11 Raven Biotechnologies, Inc. Transferrin receptor antibodies
CN109485727A (zh) * 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
FR2953841B1 (fr) 2009-12-16 2011-12-30 Centre Nat Rech Scient Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
EP2880059A1 (en) * 2012-08-02 2015-06-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of transferrin receptor antagonist for the treatment of thalassemia
CA2893794C (en) * 2012-11-08 2021-11-09 University Of Miyazaki Antibody capable of specifically recognizing transferrin receptor
EP3552631A1 (en) * 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer

Also Published As

Publication number Publication date
AU2016296321B2 (en) 2022-09-08
CY1123941T1 (el) 2022-05-27
CA2992509A1 (en) 2017-01-26
HK1256088A1 (en) 2019-09-13
CA2992509C (en) 2025-02-04
KR20180028519A (ko) 2018-03-16
RU2018106364A3 (OSRAM) 2019-08-22
PL3325509T3 (pl) 2021-07-19
US11230605B2 (en) 2022-01-25
CN107849136A (zh) 2018-03-27
RU2018106364A (ru) 2019-08-22
IL257065A (en) 2018-03-29
SI3325509T1 (sl) 2021-07-30
AU2016296321A1 (en) 2018-01-25
KR102690998B1 (ko) 2024-07-31
JP2018521691A (ja) 2018-08-09
US20220119543A1 (en) 2022-04-21
EP3325509B1 (en) 2020-12-16
SMT202100134T1 (it) 2021-05-07
WO2017013230A1 (en) 2017-01-26
EP3325509A1 (en) 2018-05-30
RS61586B1 (sr) 2021-04-29
HUE053296T2 (hu) 2021-06-28
US12037408B2 (en) 2024-07-16
RU2737637C2 (ru) 2020-12-01
PT3325509T (pt) 2021-03-12
DK3325509T3 (da) 2021-03-08
CN107849136B (zh) 2022-04-01
HRP20210393T1 (hr) 2021-04-30
BR112018000650A2 (en) 2018-09-18
LT3325509T (lt) 2021-06-10
ES2860988T3 (es) 2021-10-05
US20190092870A1 (en) 2019-03-28
MX2018000569A (es) 2018-09-27
IL257065B (en) 2022-07-01

Similar Documents

Publication Publication Date Title
JP6858185B2 (ja) 増殖性および炎症性疾患の処置における抗ＴｆＲ抗体およびその使用
JP7295916B2 (ja) Ｐｓｍａおよびｃｄ３に対する二重特異性を有するｔ細胞エンゲージ抗体コンストラクト
JP7412521B2 (ja) Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体
KR102094022B1 (ko) 항-cd38 항체 및 감쇠 인터페론 알파-2ｂ와의 융합체
CN104271602B (zh) 双特异性抗体
JP7373650B2 (ja) 抗ｐｄ－ｌ１シングルドメイン抗体
KR102847971B1 (ko) 항체-약물 컨쥬게이트 및 이의 암 치료 용도
JP7554781B2 (ja) 抗ｃｅａｃａｍ５モノクローナル抗体およびその調製方法およびその使用
CN105873949A (zh) 新的抗baff抗体
JP7419238B2 (ja) Ｐｄ１結合剤
KR20220024211A (ko) 항-cd47 항체 및 그것의 사용
CN114641503B (zh) 抗cd371抗体及其用途
JP2023544140A (ja) 新規の抗クローディン１８抗体
JP6853392B2 (ja) 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
HK1256088B (en) Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders
TW202502826A (zh) 抗ｇｐｒｃ５ｄ／ｂｃｍａ／ｃｄ３三特異性抗體的製備及其用途
BR112018000650B1 (pt) Anticorpos anti-trf e sua utilização no tratamento de transtornos proliferativos e inflamatórios
HK40014200A (en) Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
HK40014200B (en) Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
JP2018087218A (ja) 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190718

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210302

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210323

R150 Certificate of patent or registration of utility model

Ref document number: 6858185

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250